Efficacy of conbination therapy of DPP4-inhibitor and alpha-GI for type-2 diabetes patient.

Efficacy of conbination therapy of DPP4-inhibitor and alpha-GI for type-2 diabetes patient. - Efficacy of conbination therapy of DPP4-inhibitor and alpha-GI for type-2 diabetes patient.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008051

Enrollment

Registered

2012-05-29

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type-2 diabetes mellitus

Interventions

On the first day, each patient receive a dose of alogliptin (25 mg

after a test meal). On the second day, each patient receive alogliptin (25 mg

after a meal) and acarbose (100 mg

immediately before a test meal). On the third day, each patient receive alogliptin (25 mg

after a test meal) and miglitol (50 mg

immediately before a test meal).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type-2 diabetes patient from 20 to 75 years old patient patients who gave informed consent

Exclusion criteria

Exclusion criteria: contraindication for taking alogliptin contraindication for taking acarbose contraindication for taking miglitol

Design outcomes

Primary

Measure	Time frame
Changing of blood Glucose,insulin,glucagon,totalGIP,active form GLP1 levels before and 30,60 and 120 min after food intake.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026